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Abstract
Background: We investigated the seropositive rates and persistence of antibody against pandemic (H1N1) 2009 virus
(pH1N1) in pregnant women and voluntary blood donors after the second wave of the pandemic in Nanjing, China.
Methodology/Principal Findings: Serum samples of unvaccinated pregnant women (n=720) and voluntary blood donors
(n=320) were collected after the second wave of 2009 pandemic in Nanjing. All samples were tested against pH1N1 strain
(A/California/7/2009) with hemagglutination inhibition assay. A significant decline in seropositive rates, from above 50% to
about 20%, was observed in pregnant women and voluntary blood donors fifteen weeks after the second wave of the
pandemic. A quarter of the samples were tested against a seasonal H1N1 strain (A/Brisbane/59/2007). The antibody titers
against pH1N1 strain were found to correlate positively with those against seasonal H1N1 strain. The correlation was
modest but statistically significant.
Conclusions and Significance: The high seropositive rates in both pregnant women and voluntary blood donors suggested
that the pH1N1 virus had widely spread in these two populations. Immunity derived from natural infection seemed not to
be persistent well.
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Introduction
In April 2009, an emergent pandemic influenza strain, now
called pandemic (H1N1) 2009 (pH1N1), infected thousands of
persons in Mexico and the United States and then spread rapidly
throughout the globe [1–4]. The first case in Mainland China was
identified on 11 May 2009, while in Nanjing (the capital city of
Jiangsu province with 6.44 million people) it was in mid-June
2009. The epidemic in Nanjing reached its peak in mid-September
and late November, and attenuated to baseline levels by late
December, 2009. As in previous influenza epidemics and
pandemics, pregnant women appeared to be at higher risk of
serious consequences following infection with pH1N1virus [5–11].
In fact, pregnant women accounted for 25% of serious cases of
pH1N1reported to the Jiangsu Provincial Center for Disease
Prevention and Control (JSCDC). Therefore, it is critical to
investigate the seropositive rates and antibody persistence in
pregnant population which may provide valuable information for
decision-making on immunization strategies and other prevention
measures for pregnant women. Several cross sectional studies had
revealed the seroprevalence of antibody against pandemic (H1N1)
2009 strain in the general population after the pandemic [12–14].
However, data on seroprevalence of pH1N1 antibody in pregnant
women were limited, especially the antibody persistence after the
pandemic. The study aimed to describe the seropositive rates and
persistence of antibody against pH1N1in pregnant women after
the second wave of the pandemic.
Methods
Ethics statement
Serum samples were collected from the residual sera used for
routine check-up of pregnant women, and from stored sera of
voluntary blood donors without additional collection. All the
samples were collected and analyzed anonymously. Written
informed consents were received from all participants. The study
was approved by the Ethics Committee of JSCDC.
Samples collection
The samples were collected four times after the second wave of
pandemic (H1N1) 2009, i.e. on January 1–10, January 20–28,
February 20–28 and March 20–28, 2010 (Figure 1). A total of
1040 serum samples were collected, of which 720 samples (180
each time) from pregnant women were collected anonymously in
two large maternity and children hospitals in Nanjing. And 320
samples (80 each time) from voluntary blood donors were
randomly collected anonymously as control in Jiangsu Province
Blood Center in Nanjing. Demographic characteristics such as
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enrolled pregnant women were equally distributed among the four
sampling times. The gestational weeks were taken into account to
ensure that the participants were pregnant at the time of virus
circulation. All participants did not receive pH1N1 and seasonal
influenza vaccines before bleeding.
Hemagglutination inhibition (HAI) assay
All serum samples were tested with HAI assay against pH1N1
strain (A/California/7/2009) and a quarter of samples was tested
against a seasonal H1N1 strain (A/Brisbane/59/2007), which was
conducted as previously described [15,16]. To inactivate non-
specific inhibitors, all serum samples were first treated with
receptor destroying enzyme (Cholera filtrate, GIGMA) and then
serially diluted into 2-fold dilution starting with a 1:10 dilution in
V-bottom 96-well micro titer plates. An equal volume of virus
dilution containing about 4HA units/50 ml was added to each
well. The plates were incubated at room temperature for 50 min
followed by addition of freshly prepared 1% chicken erythrocyte,
and then incubated at 25uC for 30 min. The HAI titer was
determined by the reciprocal of the last dilution showing no
agglutination of erythrocyte. Both positive and negative controls
were included in each plate. Samples with HAI titer $1:40 were
considered seropositive. It was generally accepted that serum HAI
titers of 40 are associated with at least a 50% reduction in risk of
infection or disease with seasonal influenza viruses in human
population [12].
Sample Size
Sample size calculations were performed by EpiCalc (v1.02)
based on an estimated seroprevalence of 30%, which indicated that
80 samples would be required per time to detect seroprevalence +/
210% within a 95% confidence interval. The precision would
increase to +/26.7% if the sample size were more than 180.
Statistical analysis
Kolmogorov-Smirnov test was used to test the normality of
data. The differences of non-normal distribution data were
compared by Kruskal-Wallis test. Spearman correlation coeffi-
cients were calculated to describe the correlation between
antibody titers against pH1N1 and seasonal H1N1 viruses.
Cochran-Armitage test was used for trend test across the four
sampling times. Chi square tests were used to compare the
differences of seropositive rates between pregnant women and
voluntary blood donors among the four sampling times. All the
statistical analysis was performed with Statistical Analysis System
software (9.1.3; SAS Institute, Cary, NC, USA).
Results
A total of 720 pregnant women and 320 voluntary blood donors
were included in final analysis. There were no statistically
significant differences in age among the four sampling times
(P=0.808). The gestational weeks in the women participants
showed an increase trend across the sampling times (Table 1). In
fact, 98.06% of the enrolled pregnant women had been pregnant
prior to the pandemic and the remained became pregnant during
the first 1–2 weeks of the pandemic. In voluntary blood donors,
the median and interquartile range of ages were 24 years and 21–
30 years, respectively, and the sex ratio was 1.02.
At the first and second sampling times in January, about 4 and 7
weeks after the second wave, the seropositive rates against pH1N1
were 51.67% (95%CI, 44.30%–59.04%) and 50.56% (95%CI,
43.18%–57.93%) in pregnant women, respectively, while 58.75%
(95%CI, 47.73%–69.77%) and 42.50% (95%CI, 31.43%–53.57%)
in voluntary blood donors, respectively. The seropositive rates
showed no significant differences between the two populations.
The seropositive rates declined significantly (P for trend ,0.0001)
afterward. At the third and fourth sampling times in February and
Figure 1. Sampling times and epidemic curve. Sampling times of serologic survey (Jan 1–Mar 28, 2010) shown relative to epidemic curve of
pH1N1 cases and percent of ILI (influenza-like illness, ILI %) accounted for out-patient and emergency cases.
doi:10.1371/journal.pone.0017995.g001
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seropositive rates were 18.89% (95%CI, 13.12%–24.66%) and
19.44% (95%CI, 13.61%–25.28%) in pregnant women, respec-
tively, while 26.67% (95CI, 17.35%–35.98%) and 20.00%
(95%CI, 11.04%–28.96%) in voluntary blood donors, respectively.
No significant differences were found either between pregnant
women and voluntary blood donors (Table 2, Figure 2).
To detect possible cross-reaction between pH1N1and seasonal
H1N1 viruses, serum samples collected during Jan 1–10 were
tested simultaneously against a seasonal H1N1 influenza strain, A/
Brisbane/59/2007, which was recommended by the World
Health Organization for vaccine manufacturers in the last 3
influenza seasons [17–19]. The HAI titers against pH1N1 strain
were found to correlate positively with those against seasonal
H1N1 strain. The correlation was modest but statistically
significant (R=0.36, P,0.0001 for Spearman test).
Discussion
The emergence of pH1N1 strain presented a public health
challenge. The investigation on epidemiological features was
critical for influenza prevention and control. Serologic survey was
a useful tool to understand the seropositive rates and antibody
persistence after natural infection, especially in some populations
at high risk, such as pregnant women. In this study, the
seropositive rates and persistence of antibodies in unvaccinated
pregnant women and voluntary blood donors were determined in
the post-pandemic period in Nanjing, China, contributing to our
knowledge on immune status in the pregnant women and
voluntary blood donors.
Four weeks after the second wave of the pandemic in Nanjing,
the seropositive rates remained somewhat high in pregnant
women and voluntary blood donors, which were similar to those
in a previous report in Norway (44.9% overall, 65.3%highest)
[20]. However, the seropositive rates in our study were much
higher than those in pregnant women (15.7% overall, 20.8%high-
est, n=296) in Manitoba of Canada after the first wave of
pandemic (August 2009) [21], in general population (14.5%) in
United Kingdom after the first wave of pandemic [13], and in
Pittsburgh-area residents (21%) in USA one month after the
second wave (mid-November and early December 2009) [12].
One of the possible reasons for the difference might be the
different infection rates between the first and second wave of
pandemic. The age composition of study population could also
impact the seropositive rates since young adults were at higher risk
of infection with pH1N1 virus. In addition, the susceptibility to the
pandemic virus may relate to ethnic, health behavior and
vaccination history. And the pre-pandemic baseline level of
antibody and the sensitivity of HAI assay could be the possible
reasons [22].
Deng et al conducted a serological survey in 710 residents in
Beijing and found a seropositive rate of 14.0% overall but a lower
rate of 4.5% in individuals aged 60 years or more by comparison
with individuals in other age groups (0–5, 6–17, 18–59 years) [23],
which were significantly different from our findings and other
seroepidemiological studies [12,13,24]. At least two reasons could
account for this diversity. Firstly, most of the participants in the
study of Deng et al were recruited from outpatients with various
clinical conditions, where a selection bias might produce.
Secondly, the second wave of pandemic in China was from
November 22 to November 29, 2009 according to China influenza
monitoring weekly written by China CDC (http://www.cnic.org.
cn/chn/). And in Nanjing, the second wave was from November
30 to December 6, 2009 (Figure 1). The sampling time of Deng
et al was from 29 November to 5 December, 2009, by which the
duration of antibody response against natural infection might not
be long enough.
At present, data on persistence of antibodies against
pH1N1virus due to natural infection were limited. The results
derived from our study may address the gap. We found that the
seropositive rates derived from natural infection declined signif-
icantly in both pregnant women and voluntary blood donors after
the second wave of the pandemic, from above 50% to about 20%
in an 11-week interval. Prior to the pandemic, unvaccinated
population had very low baseline HAI titers against the emergent
strain pandemic (H1N1) 2009. Song et al found that pre-
vaccination low HAI titer (,1:40) was associated with early
decline of HAI titer [25]. In a previous survey conducted in
regions surrounding Nanjing in November 2008 by JSCDC, the
seropositive rate (HAI titers $1:40) of antibody against pandemic
H1N1 was found to be only 3.64% [26]. The low baseline HAI
titers in naı ¨ve population might account for the early decline of
pH1N1 titers in this study. Similarly, the HAI titers against H5N1
strain were very low in naive population as well. It was found that
individuals’ antibody levels also significantly declined several
months after the second dose of H5N1 vaccine [27]. However, a
third dose of the same vaccine could significantly boost immune
responses [27]. Accordingly, vaccination with the same
pH1N1strain would be needed for the naturally infected
population in our study to acquire enough immunity. In addition,
memory T cells also play a role in the cellular immune response to
secondary infection [28]: flu-specific CD8+T-lymphocyte respons-
es are important in decreasing disease severity and facilitating viral
clearance [29], and CD4+ T cells are able to mediate potent
Table 1. Ages and gestational weeks of pregnant women
when serum samples were collected.
Sampling
times
Weeks after
the second
wave
Age
(median, quartiles),
years
Gestational weeks
(median, quartiles)
Jan 1–10 4 weeks 28 (26–30) 35 (31–38)
Jan 20–28 7 weeks 28 (27–31) 36 (32–38)
Feb 20–28 11 weeks 28 (27–30.75) 37 (32–40)
March 20–28 15 weeks 28 (26–31.75) 37 (31.25–40)
P* 0.808 0.004
*Kruskal-Wallis Test.
doi:10.1371/journal.pone.0017995.t001
Table 2. Seropositive rates of antibodies against pH1N1 in
pregnant women and voluntary blood donors at the 4
sampling times.
Sampling
times
Pregnant
(%, 95%CI)
Voluntary blood
donors (%, 95%CI) P *
Jan 1–10 51.67 (44.30–59.04) 58.75 (47.73–69.77) 0.29
Jan 20–28 50.56 (43.18–57.93) 42.50 (31.43–53.57) 0.23
Feb 20–28 18.89 (13.12–24.66) 26.67 (17.35–35.98) 0.14
March 20–28 19.44 (13.61–25.28) 20.00 (11.04–28.96) 0.92
P trend
{ ,0.0001 ,0.0001
Seropositive rates, Proportion of titers of 1:40 or more (%).
*Chi square tests.
{Cochran-Armitage test.
doi:10.1371/journal.pone.0017995.t002
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impact of the significant decline in seropositive rates of antibodies
on the protection against secondary infection of the naturally
infected population needs further investigation.
The protein sequence similarity of the pandemic H1N1 2009
and human seasonal influenza H1N1 is about 80% [31]. In our
study, a modest but statistically significant correlation between
HAI titers of these two strains was found, indicating a possible
cross-reaction. In a previous survey conducted in regions
surrounding Nanjing prior to the pandemic, the overall seropos-
itive rates of antibodies against pH1N1 were 3.64%, and 0, 6.20%,
3.75% and 5.06% in subgroups of 3–11years, 12–17years, 18–
60years and $60 years, respectively [26]. These pre-pandemic
data also supported possible cross-reaction. In a previous study
conducted in a population in U.S., authors also found a modest
correlation between seasonal A/Brisbane/59/2007 H1N1 and
pH1N1 [12]. In addition, Chen et al. found antibodies derived
from natural infection with pH1N1 showed cross reaction with
seasonal influenza viruses. There was a four-fold or greater
increase in cross-reactive antibody titers to seasonal A/Brisbane/
59/2007 H1N1 in 20% of RT-PCR confirmed pandemic (H1N1)
2009 infected participants [32].
In conclusion, the seropositive rates and persistence of
antibodies in unvaccinated pregnant women and voluntary blood
donors were determined after the second wave of 2009 pandemic
in Nanjing, China, contributing to our understanding on the
changes of immunity derived from natural infection. Our findings
of high seropositive rates in pregnant women and voluntary blood
donors, suggested that pandemic (H1N1) 2009 strain had widely
spread in these populations. Further efforts would be needed to
investigate the impact of declined antibody level on secondary
infection of the same strain.
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